Filtered By:
Condition: Thrombosis
Procedure: Heart Transplant

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 180 results found since Jan 2013.

HCV false positive immunoassays in patients with LVAD: a potential trap!
Over the last decades, left ventricular assist device (LVAD) has become the therapeutic choice for patients with advanced heart failure [1]. Patients benefit from a LVAD in different situations: as a bridge to cardiac transplantation or to recover a better heart function, or as a destination therapy [2]. The outcome of patients with LVAD has improved but it requires a close monitoring to avoid complications as bleeding, stroke, malignant arrhythmias, pump thrombosis and infection.
Source: Journal of Clinical Virology - March 10, 2016 Category: Virology Authors: Amélie Heinrichs, Martine Antoine, Deborah Steensels, Isabel Montesinos, Marie-Luce Delforge Tags: Short Communication Source Type: research

Watchful Waiting in Continuous-Flow Left Ventricular Assist Device Patients With Ongoing Hemolysis Is Associated With an Increased Risk for Cerebrovascular Accident or Death Original Articles
Conclusions— Hemolysis refractory to intensification of antithrombotic therapy identifies continuous-flow left ventricular assist device patients at major risk for CVA and death. Early device exchange should be considered to minimize these risks.
Source: Circulation: Heart Failure - May 9, 2016 Category: Cardiology Authors: Levin, A. P., Saeed, O., Willey, J. Z., Levin, C. J., Fried, J. A., Patel, S. R., Sims, D. B., Nguyen, J. D., Shin, J. J., Topkara, V. K., Colombo, P. C., Goldstein, D. J., Naka, Y., Takayama, H., Uriel, N., Jorde, U. P. Tags: Cardiovascular Surgery, Transplantation, Cerebrovascular Disease/Stroke Original Articles Source Type: research

French Intensive Care Society, International congress - Réanimation 2016.
C, Sauneuf B, Verrier P, Pottier V, Orabona M, Samba D, Viquesnel G, Lermuzeaux M, Hazera P, Hanouz JL, Parienti JJ, Du Cheyron D, Demoule A, Clavel M, Rolland-Debord C, Perbet S, Terzi N, Kouatchet A, Wallet F, Roze H, Vargas F, Guérin C, Dellamonica J, Jaber S, Similowski T, Quenot JP, Binquet C, Vinsonneau C, Barbar SD, Vinault S, Deckert V, Lemaire S, Hssain AA, Bruyère R, Souweine B, Lagrost L, Adrie C, Jung B, Daurat A, De Jong A, Chanques G, Mahul M, Monnin M, Molinari N, Lheureux O, Trepo E, Hites M, Cotton F, Wolff F, Surin R, Créteur J, Vincent JL, Gustot T, Jacobs F, Taccone FS, Neuville M, Timsit JF, El-Hel...
Source: Australian Family Physician - May 31, 2016 Category: Primary Care Authors: Jaillette E, Girault C, Brunin G, Zerimech F, Chiche A, Broucqsault-Dedrie C, Fayolle C, Minacori F, Alves I, Barrailler S, Robriquet L, Delaporte E, Thellier D, Delcourte C, Duhamel A, Nseir S, Valette X, Desmeulles I, Savary B, Masson R, Seguin A, Daubi Tags: Ann Intensive Care Source Type: research

St. Jude Medical ’ s HeartMate 3 implantable pump beats HeartMate II in pivotal trial
The next-generation HeartMate 3 implantable pump St. Jude Medical (NYSE:STJ) acquired when it paid $3 billion for Thoratec last year proved superior to the older HeartMate II device at 6 months in pivotal clinical trial results released today. The Momentum 3 study enrolled more than 1,000 patients for a short-term outcome after 6 months and a longer-term, 2-year outcome; the initial 6-month data comes from 294 subjects. Unlike the HeartMate II device, which uses an axial-flow pump, the HeartMate 3 device uses a centrifugal-flow pump designed to reduce the risk of blood clots. The primary endpoint at 6 months was a compo...
Source: Mass Device - November 16, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Cardiac Assist Devices Cardiovascular Clinical Trials American Heart Assn. New England Journal of Medicine St. Jude Medical Thoratec Corp. Source Type: news

Building a bioartificial heart: Obstacles and opportunities
The growing numbers of patients with heart failure, both in the United States and around the globe, has led to a pressing need for new therapies. Heart transplantation is a very restricted option due to the limited number of donor hearts available —currently approximately 2800 per year in the United States. Transplant patients also have to take immunosuppressive drugs for the rest of their lives. Ventricular assist devices, used either as bridge to transplant or destination therapy, can prolong patient survival, but present a number of comp lications, including thrombosis, stroke, and infection.
Source: The Journal of Thoracic and Cardiovascular Surgery - January 13, 2017 Category: Cardiovascular & Thoracic Surgery Authors: Martha S. Lundberg, J. Timothy Baldwin, Denis B. Buxton Tags: Feature Expert opinion Source Type: research

Surgical occlusion of the left atrial appendage and thromboembolic complications in left ventricular assist device patients
Thromboembolic complications (TEC) are major adverse events for patients supported by left ventricular assist devices (LVADs). Despite anticoagulation, TEC such as stroke or pump thrombosis still occur in 6.5% of patients.1 Risk of TEC increases with longer duration of device support and is likely a greater risk in destination therapy patients. Surgical or percutaneous occlusion of the left atrial appendage (LAAO) reduces TEC in patients with atrial fibrillation.2,3 The LAA may also be a source of thromboembolism for systolic heart failure patients, even in sinus rhythm.
Source: The Journal of Heart and Lung Transplantation - January 29, 2017 Category: Transplant Surgery Authors: Rebecca S. Lewis, Lian Wang, Kateri J. Spinelli, Gary Y. Ott, Jacob Abraham Source Type: research

Surgical occlusion of the left atrial appendage and thromboembolic complications in patients with left ventricular assist devices
Thromboembolic complications (TECs) are major adverse events for patients supported by left ventricular assist devices (LVADs). Despite anti-coagulation, TECs such as stroke or pump thrombosis occur in 6.5% of patients.1 Risk of TECs increases with longer duration of device support, and the risk is likely greater in patients receiving LVADs as destination therapy. Surgical or percutaneous occlusion of the left atrial appendage (LAA) reduces TECs in patients with atrial fibrillation.2,3 The LAA may also be a source of thromboembolism for patients with systolic heart failure, including patients in sinus rhythm.
Source: The Journal of Heart and Lung Transplantation - January 29, 2017 Category: Transplant Surgery Authors: Rebecca S. Lewis, Lian Wang, Kateri J. Spinelli, Gary Y. Ott, Jacob Abraham Tags: Research Correspondence Source Type: research

Outcomes of Asian-Americans Undergoing Left Ventricular Assist Device Implantations as a Bridge to Transplant or Destination Therapy: An INTERMACS Analysis
Previous studies have demonstrated significant differences between Asians and Caucasian white populations in their propensity for stroke, coronary artery disease, heart failure, inflammation, bleeding and thrombosis. Therefore, we hypothesized that Asian Americans with end stage heart failure undergoing treatment with durable left ventricular assist devices (LVAD) exhibit a different morbidity and mortality risk profile when compared to non-Asian and white Americans populations.
Source: The Journal of Heart and Lung Transplantation - March 25, 2017 Category: Transplant Surgery Authors: J.R. Wever Pinzon, W. Wang, N. Hu, R. Larsen, T. Yu, L. Yin, I. Taleb, A. Koliopoulou, S. Mckellar, J. Stehlik, J. Fang, A. Kfoury, C. Selzman, S. Drakos Source Type: research

Low Dose tPA as a Therapeutic Strategy in Suspected Pump Thrombosis in HeartMate II
Tissue plasminogen activator (tPA) is a known treatment for DVT and thromboembolic stroke. Our study aim was to determine the safety and efficacy of a low dose tPA protocol in suspected pump thrombosis in HMII.
Source: The Journal of Heart and Lung Transplantation - March 25, 2017 Category: Transplant Surgery Authors: A.S. Cruz-Solbes, M.I. Achi, J. Amione-Guerra, E. Karanja, B. Trachtenberg, A. Bhimaraj, J. Estep, G. Torre-Amione, I. Hussain, M. Park, B. Bruckner, A. Guha Source Type: research

Management of RVAD Thrombosis in Biventricular HVAD Supported Patients
Pump thrombosis confers significant morbidity and mortality in left ventricular assist device (LVAD) supported patients. Particularly in HVAD, therapeutic approaches including thrombolysis, or adjusting anticoagulation have been recommended as initial treatment but are associated with hemorrhagic stroke and death. Conversely, device exchange has been recommended as a preferred choice with low morbidity-mortality. Biventricular support (BIVAD) utilizing 2 HVAD systems has been proven as a novel way to manage critically ill individuals with biventricular failure.
Source: The Journal of Heart and Lung Transplantation - March 25, 2017 Category: Transplant Surgery Authors: J. Silva Enciso, M. Brambatti, H. Tran, G.V. Pretorius, E. Adler Source Type: research

Sildenafil Reduces Risk of Ischemic Stroke and Pump Thrombosis with Ongoing Low Level Hemolysis During Heart Mate II Support
Low level hemolysis after Heart Mate (HM) II implantation, as evident by an elevated discharge lactate dehydrogenase (LDH) level>400 U/L, is linked to subsequent thrombotic events. Free hemoglobin from ongoing hemolysis scavenges nitric oxide (NO) to create a NO deficiency which can augment platelet function. We hypothesized the potentiation of NO signaling during low level hemolysis with a phosphodiesterase-5 inhibitor, sildenafil, may lead to reduced thrombotic events.
Source: The Journal of Heart and Lung Transplantation - March 25, 2017 Category: Transplant Surgery Authors: O. Saeed, S. Rangasamy, A. Luke, S.P. Patel, D.B. Sims, J. Shin, M. Reyes Gil, M.J. Slepian, H.H. Billett, D.J. Goldstein, U.P. Jorde Source Type: research

Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure.
CONCLUSIONS : In this secondary analysis of the MOMENTUM 3 trial, the HM3 LVAS demonstrated greater freedom from HRAEs in comparison with the HMII LVAS at 6 months. CLINICAL TRIAL REGISTRATION : URL: http://clinicaltrials.gov. Unique identifier: NCT02224755. PMID: 28385948 [PubMed - as supplied by publisher]
Source: Circulation - April 6, 2017 Category: Cardiology Authors: Uriel N, Colombo PC, Cleveland JC, Long JW, Salerno C, Goldstein DJ, Patel CB, Ewald GA, Tatooles AJ, Silvestry SC, John R, Caldeira C, Jeevanandam V, Boyle AJ, Sundareswaran KS, Sood P, Mehra MR Tags: Circulation Source Type: research

Ventricular assist devices for the failing univentricular circulation.
Authors: Buratto E, Shi WY, Ye XT, Konstantinov IE Abstract INTRODUCTION: Improved survival following single ventricle palliation has led to a large population of patients with a Fontan circulation, many of whom will eventually develop Fontan failure. Many of these patients will require heart transplantation. However, more than half of these patients have Fontan failure despite preserved ventricular function. Increasing experience with ventricular assist devices (VAD) in children has paved the way for VAD support in those with failing univentricular circulation. Areas covered: The use of VADs to support the failing...
Source: Expert Review of Medical Devices - May 24, 2017 Category: Medical Devices Tags: Expert Rev Med Devices Source Type: research

Pathophysiologic role of ischemia reperfusion injury: a review
Publication date: Available online 19 June 2017 Source:Journal of Indian College of Cardiology Author(s): Vishal Kumar Vishwakarma, Prabhat Kumar Upadhyay, Jeetendra Kumar Gupta, Harlokesh Narayan Yadav Ischemic heart disease (IHD) is the major cause of morbidity and mortality all over the world. World health organization (WHO) in 2002 assumed that IHD may be the major leading cause of death by 2020. An estimated 17 million people died from cardiovascular diseases (CVS) globally. Of these deaths, 7 million people died by ischemia heart disease and 6.2 million by stroke. Ischemia is defined as an insufficient supply of the...
Source: Journal of Indian College of Cardiology - June 19, 2017 Category: Cardiology Source Type: research

Clinical Journey of Severe Heart Failure Patients after Left Ventricular Assistance Device Implant
This study aims to model the post-operative care pathway of patients after LVAD implementation using INTERMACS data.
Source: Journal of Cardiac Failure - August 1, 2017 Category: Cardiology Authors: Faezeh Movahedi, Lisa Lohmueller, Yiye Zhang, Rema Padman, James Antaki Source Type: research